T
Tina Matlawski
Researcher at University of Pennsylvania
Publications - 5
Citations - 810
Tina Matlawski is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 3 publications receiving 398 citations.
Papers
More filters
Journal ArticleDOI
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer,Joseph A. Fraietta,Megan M. Davis,Adam D. Cohen,Kristy L. Weber,Eric Lancaster,Patricia A. Mangan,Irina Kulikovskaya,Minnal Gupta,Fang Chen,Lifeng Tian,Vanessa E. Gonzalez,Jun Xu,In-Young Jung,J. Joseph Melenhorst,Gabriela Plesa,Joanne Shea,Tina Matlawski,Amanda Cervini,Avery L. Gaymon,Stephanie Desjardins,Anne Lamontagne,January Salas-Mckee,Andrew D. Fesnak,Don L. Siegel,Bruce L. Levine,Julie K. Jadlowsky,Regina M. Young,Anne Chew,Wei-Ting Hwang,Elizabeth O. Hexner,Beatriz M. Carreno,Christopher L. Nobles,Frederic D. Bushman,Kevin R. Parker,Yanyan Qi,Ansuman T. Satpathy,Howard Y. Chang,Yangbing Zhao,Simon F. Lacey,Carl H. June +40 more
TL;DR: This first-in-human, phase 1 clinical trial was designed to test the safety and feasibility of multiplex CRISPR-Cas9 gene editing of T cells from patients with advanced, refractory cancer and found the persistence of the T cells expressing the engineered TCR was much more durable than in three previous clinical trials during which T cells were infused.
Journal ArticleDOI
Phase I trial of autologous cMET-directed CAR-t cells administered intravenously in patients with melanoma & breast carcinoma.
Payal D. Shah,Alexander C. Huang,Xiaowei Xu,Paul J. Zhang,Robert Z. Orlowski,Tina Matlawski,Joanne Shea,Amanda Cervini,Ravi K. Amaravadi,Julia Tchou,Lynn M. Schuchter,E. John Wherry,Gerald P. Linette,Rosemarie Mick,Irina Kulikovskaya,Simon F. Lacey,Gabriela Plesa,Carl H. June,Robert H. Vonderheide,Tara C. Mitchell +19 more
TL;DR: A pilot phase I clinical trial in patients with advanced relapsed/refractory melanoma and metastatic triple-negative breast cancer is conducted using a novel and scalable approach called “cell reprograming”.
Journal ArticleDOI
First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma
Edward A. Stadtmauer,Adam D. Cohen,Kristy L. Weber,Simon F. Lacey,Vanessa E. Gonzalez,J. Joseph Melenhorst,Joseph A. Fraietta,Gabriela Plesa,Joanne Shea,Tina Matlawski,Amanda Cervini,Patricia A. Mangan,Avery L. Gaymon,Stephanie Desjardins,Eric Lancaster,January Salas-Mckee,Megan M. Suhoski,Andrew D. Fesnak,Matthew O'Rourke,Anne Lamontagne,Don L. Siegel,Regina M. Young,Anne Chew,Christopher L. Nobles,Frederic D. Bushman,Howard Y. Chang,Ansuman T. Satpathy,Yangbing Zhao,Wei-Ting Hwang,Elizabeth O. Hexner,Carl H. June +30 more
TL;DR: Tmunity: Membership on an entity's Board of Directors or advisory committees, Research Funding; novartis: Research Funding, other: scientific founder, for which he has founders stock but no income, Patents & Royalties.
Journal ArticleDOI
Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy
Jakub Svoboda,James N. Gerson,Daniel J. Landsburg,Elise A. Chong,Stefan K. Barta,Sunita Dwivedy Nasta,Marco Ruella,Elizabeth O. Hexner,Amy Marshall,R.M. Leskowitz,Megan Four,Joanne Shea,Tina Matlawski,Amanda Cervini,Megan M. Davis,Mercy Gohil,John Scholler,Donald Hasenmayer,Juliana Rojas Amortegui,Andrea L. Brennan,Gabriela Plesa,Wei-Ting Hwang,David L. Porter,Joseph A. Fraietta,Stephen J. Schuster,Carl H. June +25 more
Journal ArticleDOI
Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
Payal D. Shah,Alexander C. Huang,Xiaowei Xu,Robert Z. Orlowski,Ravi K. Amaravadi,Lynn M. Schuchter,Paul Zhang,Julia Tchou,Tina Matlawski,Amanda Cervini,Joanne Shea,Joan Gilmore,Lester Lledo,Karen Dengel,Amy Marshall,E. John Wherry,Gerald P. Linette,Andrea L. Brennan,Vanessa E. Gonzalez,Irina Kulikovskaya,Simon F. Lacey,Gabriela Plesa,Carl H. June,Robert H. Vonderheide,Tara C. Mitchell +24 more
TL;DR: In this paper , the safety and feasibility of intravenous RNA-electroporated CAR T cells targeting the cell-surface antigen cMET were evaluated in patients with metastatic melanoma and metastatic triple-negative breast cancer.